Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.

Kosuke Ebina Toru Hirano Yuichi Maeda Wataru Yamamoto Motomu Hashimoto Koichi Murata Tohru Takeuchi Koji Nagai Yonsu Son Hideki Amuro Akira Onishi Sadao Jinno Ryota Hara Masaki KatayamaKeiichi YamamotoAtsushi Kumanogoh Makoto Hirao

Published in: Clinical rheumatology (2020)

Switching to ABT in TCZ-treated patients led to higher retention as compared with TNFi. Switching to TCZ in ABT-treated patients tended to lead to higher retention due to effectiveness, although total retention was similar as compared with TNFi. Key Point • This is the first retrospective, multi-center study aimed to clarify the retention rates of secondary bDMARDs or JAKi in patients with RA who were primarily being treated by TCZ or ABT as the first bDMARDs.

Keyphrases

newly diagnosed
end stage renal disease
rheumatoid arthritis
chronic kidney disease
randomized controlled trial
prognostic factors
peritoneal dialysis
systematic review
patient reported outcomes
systemic sclerosis
interstitial lung disease